Chi-Med
AIM: £50.50 (+0) | Nasdaq: $34.00 (+0.76)
Search
About Us
Innovation Platform
Overview
Our Pipeline
R&D Approach
Key Corporate Partnerships
Innovation News
Commercial Platform
Overview
Prescription Drugs
Competitive Advantages
Main Products
Consumer Health
Commercial Platform News
News & Presentations
Recent News
All RNS & Press Releases
Presentations & Publications
Leadership & Governance
Our Leadership
Board of Directors
Senior Management
Corporate Information
Terms of Reference & Policies
Financial Results
Overview
Financial Highlights
Chairman's Statement
Financial Reports
SEC Filings
Shareholder Information
Overview
Share Price & Chart
Major Shareholders
Events, Circulars & Forms
Analyst Coverage
Dual-listing FAQs
Information for Shareholders
Warning to Shareholders
AIM Rule 26
About Us
Innovation Platform
Overview
Our Pipeline
R&D Approach
Key Corporate Partnerships
Innovation News
Commercial Platform
Overview
Prescription Drugs
Competitive Advantages
Main Products
Consumer Health
Commercial Platform News
News & Presentations
Recent News
All RNS & Press Releases
Presentations & Publications
Leadership & Governance
Our Leadership
Board of Directors
Senior Management
Corporate Information
Terms of Reference & Policies
Financial Results
Overview
Financial Highlights
Chairman's Statement
Financial Reports
SEC Filings
Shareholder Information
Overview
Share Price & Chart
Major Shareholders
Events, Circulars & Forms
Analyst Coverage
Dual-listing FAQs
Information for Shareholders
Warning to Shareholders
AIM Rule 26
Fruquintinib Approved
CEO Christian Hogg on CNBC Squawk Box
Watch Interview Excerpt
2018 H1 Results
Financial Results and Update on R&D Programs
Announcement & presentation webcast
View More
Fruquintinib in JAMA
Full text of FRESCO colorectal cancer trial published
Read Abstract
Royal Society of Medicine
CEO Christian Hogg speaks at
RSM Medical Innovations Summit
Watch Presentation
AstraZeneca & Chi-Med
Harnessing the power of Chinese scientific innovation
Learn More
Latest News
Innovation Platform
|
29 Nov 2018
Chi-Med Enters into Multiple Collaborations to Evaluate Combinations of Surufatinib and Fruquintinib with PD-1 Checkpoint Inhibitors
Innovation Platform
|
26 Nov 2018
Chi-Med Announces First Commercial Launch of Fruquintinib Capsules (Elunate®)
Innovation Platform
|
20 Nov 2018
Chi-Med Receives BayHelix R&D Achievement of the Year Award at BioCentury China Healthcare Summit
Innovation Platform
|
16 Nov 2018
Chi-Med Announces Phase III FALUCA Trial Results for Fruquintinib in Third-Line, Advanced Non-Small Cell Lung Cancer in China
Innovation Platform
|
18 Oct 2018
Chi-Med Initiates a Phase I Trial of HMPL-523 in Combination with Azacitidine in Elderly Patients with Acute Myeloid Leukemia in China
Current Share Price
London AIM:HCM
£50.50
+0 | 14-Dec-2018 | 08:00 BST
Nasdaq:HCM
US$34.00
+0.76 | 13-Dec-2018 | 15:59 EST
Note: 1 Nasdaq share = ½ AIM share
Latest Presentations
27 Jul 2018
2018 Half-Year Financial Results
26 Jun 2018
JAMA: Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer
4 Jun 2018
ASCO 2018: Quality-adjusted time without symptoms or toxicity (Q-TWiST) of patients with metastatic colorectal cancer treated with fruquintinib in FRESCO
4 Jun 2018
ASCO 2018: Subgroup analysis by prior anti-VEGF or anti-EGFR target therapy in FRESCO
Latest Reports
Interim Report 2018
EN
Annual Report 2017 (with Form 20-F)
EN
Interim Report 2017
EN
Share conversions between AIM & Nasdaq
Mailing list sign-up
Analyst Coverage
Bank of America Merrill Lynch
Canaccord Genuity
Deutsche Bank
Edison (link to research)
Kim Eng Securities
Panmure Gordon
Stifel
The leading China-based innovator
Our
Innovation Platform
focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases.
Learn More
A powerful commercial network in China
Our
Commercial Platform
manufactures, markets and distributes prescription and over-the-counter pharmaceuticals in China.
Learn More